Integra LifeSciences (IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline
Johnson Fistel, PLLP announced an investigation into Integra LifeSciences (IART) over whether the company adequately disclosed flooding-related disruptions at its Cincinnati manufacturing facility. Per the release, Integra said on July 29 that flooding would not materially affect 2026 guidance, but on October 2 disclosed roughly $7 million in lost Q3 revenue plus $15-$20 million of expected Q4 impact and cut 2026 revenue and EPS guidance. Shares fell approximately 21.2% to $12.68 on the October 2 news; the facility is not expected back at full manufacturing until Q2 2027.
Key figures
- Revenue Yoy
- 0
- Closing price
- 12.68
- Guidance cut eps
- adjusted EPS lowered from $2.40-$2.50 to $2.30-$2.40
- Stock decline pct
- 21.2%
- Q3 lost revenue usd
- 7000000
- Guidance cut revenue
- 2026 revenue lowered from $1.654B-$1.695B to $1.634B-$1.654B
- Q4 revenue impact usd
- $15 million to $20 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.